New promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport

Bratislava Medical Journal

Volumn 114, Issue 3, 2013, Pages 172-176

  Ginter, E ^a   Simko, V ^b  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Anti atherogenic action; Apoprotein apo A I; Apoprotein apo A II; Foam cells; High density lipoprotein cholesterol (HDL); Low density lipoprotein cholesterol (LDL); Reverse cholesterol transport

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; HUMAN; METABOLISM; OXIDATIVE STRESS; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, HDL; HUMANS; OXIDATIVE STRESS;

EID: 84875537638     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2013_037     Document Type: Review

References (26)

1. Ginter E, Simko V. Statins: the drugs for the 21st century? Bratisl Lek Listy 2009; 110 (10): 664-668.
2. European Health for All database (HFA-DB). Copenhagen, WHO Regional Offi ce for Europe, [2010] http://euro.who.int/hfadb.
3. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defi ning the role of hyperlipidemia. J Lipid Res 2005; 46: 2037-2051.
4. Sharma RK, Singh VN, Reddy HK. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc Health Risk Manag 2009; 5: 793-799.
5. Rocha VZ, Libby P. Obesity, infl ammation, and atherosclerosis. Nature Rev Cardiol 2009; 6: 399-409.
6. Francis GA. The complexity of HDL. Biochim Biophys Acta 2010; 1801 (12): 1286-1293.
7. Nicholls SJ, Uno K, Tuzcu EM et al. Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol. Curr Atheroscler Rep 2010; 12 (5): 301-307.
8. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL defi ciency and premature coronary heart disease. Curr Opin Lipidol 2010; 21 (4): 289-297.
9. Hirayama S, Miida T, Miyazaki O et al. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007; 30 (5): 1289-1291.
10. Heinecke J. HDL and cardiovascular-disease risk--time for a new approach? N Engl J Med 2011; 364 (2): 170-171.
11. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol effl ux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364 (2): 127-135.
12. Remaley AT, Warnick GR. The changing testing paradigm. Clin Lab News 2007; 33 (12).
13. Liu HR, Wu G, Zhou B et al. Low cholesteryl ester transfer protein and phospholipid transfer protein activities are the factors making three shrew and beijing duck resistant to atherosclerosis. Lipids Health Dis 2010; 9: 114.
14. Toth PP, Davidson MH. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol 2010; 4 (5): 359-364.
15. Haas MJ, Mooradian AD. Infl ammation, high-density lipoprotein and cardiovascular dysfunction. Curr Opin Infect Dis 2011; Feb 14.
16. Holzer M, Gauster M, Pfeifer T et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 2011; Jan 14.
17. Skaggs BJ, Hahn BH, Sahakian L et al. Dysfunctional, pro-infl ammatory HDL directly upregulates monocyte PDGFRß, chemotaxis and TNFa production. Clin Immunol 2010; 137 (1): 147-156.
18. van Dujinhoven FJ, Bueno-de-Mesquito HB, Calligaro M et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into cancer and nutrition.Gut 2011, March 7.
19. Burillo E, Andres EM, Mateo-Gallego R et al. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. Heart 2010; 96 (17): 1345-1351.
20. Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2010; 12 (5): 343-348.
21. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009; 6: 455-463.
22. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94 (6): 706-714.
23. Yvan-Charvet L, Kling J, Pagler T et al. Cholesterol effl ux potential and antiinfl ammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010; 30 (7): 1430-1438.
24. Cannon CP, Shah S, Dansky HM et al. Safety of Anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415.
25. Rahilly-Tierney CR, Spiro A, Vokonas P et al. Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA Normative Aging Study). Am J Cardiol 2011; 4.
26. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010; 55 (13): 1283-1299.